Previously, it was reported that the lethality of pazopanib could be significantly enhanced via knockdown of [HDAC6 + HDAC2] or [HDAC6 + HDAC10], while the knockdown of [HDAC6 + HDAC1] or [HDAC6 + HDAC3] is less effective in melanoma cells [125]. Here, HDAC6 is linked to melanoma.